Coinfection of chronic Hepatitis B and C: Impact of treatment of one virus on other viruses in Rwanda

Principal investigator: Jean Damascene Makuza
Check PI profile

Investigators

Jean Damascene Makuza, Phyu Mar Soe, Dahn De Jong, Prince Adu, Marie Paul Nisingizwe, Jeannette Iyonizera, Gallican Nshogoza Rwibasira, David Riedel, Albert Tuyishime, Sabin Nsanzimana, Naveed Janjua

Study information

  • Research Area: This is a nationwide population-based study that will concern the population screened for HBV and HCV in all Rwandan district
  • Research type: We will include data for more than 1 million individuals tested for HCV and HBV in Rwanda. This dataset has information on socio-demographic, HBV and HCV testing and treatment outcome, HIV coinfection, clinical characteristics, prescription drugs, chronic disease, complications, and death and this information will be considered.
  • Start date: Jul 27, 2021
  • End date: Jul 31, 2023

Study aim of the objectives

This project aims to describe the uptake of hepatitis c treatment among people with HCV mono-infection and those with hepatitis b virus (HBV) co-infection and assess the factors for the low treatment uptake in Rwanda. Another objective will be to characterize the treatment outcomes among people with HBV and HCV coinfection in Rwanda and factors associated with the cure rate.

Study setting/Area (Location)

Countrywide

Implementing institution

Rwanda Biomedical Center

Department/Division

IHDPC/HIV, STIs and Viral Hepatitis Division

Impact on Policy

To inform treatment guidelines

Study implementation progress

Related research

None

Login
Support